Replies to post #1 on NeuroSense Therapeutics Ltd (NRSN)

[crudeoil24]

NeuroSense Therapeutics started at buy with $7 stock price target at Maxim Group
7:32 am ET January 7, 2022 (MarketWatch)

[rakp]

Most of the time I take Israel-based pharmaceutical companies seriously and was wondering if this company is one that meets the "seriously" criteria, so to speak.

Do you perhaps support this view or at least see potential here?

Will be pleased to heat from you.

[TheFinalCD]

big day +70% recent news https://ih.advfn.com/stock-market/NASDAQ/neurosense-therapeutics-NRSN/stock-news/87378978/neurosense-therapeutics-to-present-at-american-soc

[crudeoil24]

NeuroSense Therapeutics Sees Positive Trial Results for TDP-43 Alzheimer's Treatment
9:03 am ET January 19, 2023 (Dow Jones) Print

By Chris Wack


NeuroSense Therapeutics Ltd. said it saw positive final results from a biomarker study conducted to evaluate the potential of NeuroSense's combination platform therapy for the treatment of Alzheimer's disease.

The company said preliminary results from the study showed that TDP-43, a novel biomarker, was elevated in Alzheimer's disease patients compared with a healthy control group.

Based on these preliminary results, NeuroSense said it expanded the study with a larger healthy control group to further validate the results.

NeuroSense's platform combination therapy technology has already shown a statistically significant reduction of TDP-43 in a Phase 2a clinical trial biomarker study in another neurodegenerative disease, amyotrophic lateral sclerosis, and is now being evaluated in a Phase 2b ALS double-blind clinical trial.

The company plans to start a Phase 2 double-blind proof-of-concept study in Alzheimer's disease in the first half of 2023.

NRSN